Actively Recruiting

Age: 3Years - 18Years
All Genders
ID05929976

Multi-National Nutritional Biobanking Program in Pediatric Oncology InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort

Led by Columbia University · Updated on 2025-07-22

4900

Participants Needed

8

Research Sites

N/A

Total Duration

On this page

Sponsors

C

Columbia University

Lead Sponsor

I

International Agency for Research on Cancer

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are investigating the nutritional status and its impact on treatment outcomes in children and adolescents newly diagnosed with B- or T-cell acute lymphoblastic leukemia or mixed phenotype acute leukemia. This observational study aims to create a biobank of clinical data and biological specimens from participants aged 3 to 18 years, enhancing understanding of cancer progression, prognosis, treatment toxicities, survivorship, and late effects, especially in low and middle income countries. Participants will have biological samples such as stool and blood collected at key treatment milestones including diagnosis, end of induction, beginning of maintenance, end of treatment, and one year post-treatment. Alongside, data on socioeconomic status, food security, diet, physical activity, and nutritional measurements like height, weight, and arm size will be gathered throughout the treatment period and follow-up. During the study, researchers will collect demographic, lifestyle, clinical, and nutritional information at various timepoints to accompany the biorepository. The main outcomes include establishing a multinational biobank and compiling comprehensive data on treatment-related toxicities, survival, and nutrition over seven years. Participant involvement includes multiple assessments and sample collections over the treatment course and one year after treatment ends.

CONDITIONS

Brief Title

InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort

Who Can Participate

Age: 3Years - 18Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients must be between 3 years and 18 years of age at time of assent/consent.
  • Patients must have newly diagnosed B- or T-cell ALL, or mixed phenotype acute leukemia confirmed by pathology report.
  • Patients must be receiving treatment at one of the participating centers.
Not Eligible

You will not qualify if you...

  • Patients receiving hematopoietic cell transplant.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Sample Collection

Duration - Up to 7 years

Participants provide blood and stool specimens at diagnosis, end of induction, beginning of maintenance, end of treatment, and 1-year after treatment to create a biorepository.

5 visits (in-person) over 7 years

Long-term Monitoring

Duration - Up to 7 years

Participants' sociodemographic, dietary, physical activity, clinical, and nutritional information is collected at multiple timepoints during treatment for ALL.

Multiple visits during treatment and follow-up over 7 years

Trial Site Locations

Total: 8 locations

1

Columbia University Irving Medical Center

New York, New York, United States, 10032

Active, Not Recruiting

2

Hospital de Cancer Infanto Juvenil de Barretos

Barretos, Brazil

Actively Recruiting

3

Instituto de Medicina Integral Prof. Fernando Figueira (IMIP)

Recife, Brazil

Actively Recruiting

4

Instituto de Tratamento do Câncer Infantil (ITACI)

São Paulo, Brazil

Actively Recruiting

5

Unidad Nacional De Oncologia Pediatrica

Guatemala City, Guatemala

Actively Recruiting

6

Hospital Escuela

Tegucigalpa, Honduras

Actively Recruiting

7

Post-Graduate Institute of Medical Education and Research (PGIMER)

Chandigarh, India

Actively Recruiting

8

Muhumbili Hospital

Dar es Salaam, Dar es Salaam Region, Tanzania

Actively Recruiting

Loading map...

Research Team

E

Elena Ladas, PhD, RD

M

Michelle Walters, MS, RD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

A Study Evaluating Escalating Doses of 211^At-Labeled Anti-C...

Acute Lymphoblastic Leukemia

Actively Recruiting

1 location

Phase I Study of 225Ac-DOTA-Anti-CD38 Daratumumab with Fluda...

Acute Lymphoblastic Leukemia

Actively Recruiting

1 location

A 3-cohort Randomized Study Evaluating New Immunotherapies a...

Acute Lymphoblastic Leukemia

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here